BGPT: Paper Review: LRP1 is a master regulator of tau uptake and spread

Explore by Goal

Quick Answer Copied

Bottom line

The paper argues that neuronal LRP1 is a key receptor controlling tau endocytosis (monomer/oligomer and some fibril uptake) and that LRP1 knockdown in vivo reduces trans-synaptic tau spread in a viral mosaic mouse model. Evidence includes CRISPRi knockdown screens, RAP competition, lysine-capping, mini-LRP domain mapping, tau-LRP1 interaction assays, and an in vivo AAV spread quantification workflow.

Long Answer

Paper Review (Science-focused, skeptical): “LRP1 is a master regulator of tau uptake and spread”

Nature (2020). DOI: 10.1038/s41586-020-2156-5

Known / asserted by the paper (with evidence boundaries)

LRP1 knockdown strongly reduces tau uptake in H4 cells and iPSC-derived neurons; other LDLR-family knockdowns don’t show the same strong effect (CRISPRi approach).
Some dependence on tau lysines: lysine capping on the K18 repeat fragment blocks uptake, consistent with salt-bridge/specific ligand-lysine logic for LRP1-family interactions (as argued by structural reasoning in the paper).
LRP1 ectodomain subdomains map tau binding/uptake support: mini-LRP (ectodomain) constructs show strong rescue with mLRP4 (and partial with mLRP2) for full-length tau uptake; N-terminal uptake shows different rescue patterns.
In vivo relevance (spread)**: in an AAV mosaic mouse model where donor neurons express GFP-hTau via P2A self-cleavage logic, neuronal LRP1 shRNA reduces the number of hTau+ / GFP− cells (spread readout), with notably reduced spread in cortex.

Figure-backed core claims

LRP1-specific knockdown blocks tau uptake (not transferrin).
Competition + mutants (RAP / mtRAP) support LRP1-dependent uptake.
In vivo spread is reduced by LRP1 neuronal knockdown.

Key skepticism checkpoints

CRISPRi ≠ full knockout: partial repression could leave residual LRP1 activity; interpret “almost completely blocked” as contingent on knockdown efficiency.
Model dependence: cell-line (H4) and iPSC-derived neurons may not fully reproduce in vivo endocytic states; generalization to human disease pathophysiology remains a separate question.
Spread readout is proxy-based: counting hTau+ / GFP− cells in an engineered AAV system captures spread but does not fully establish mechanisms downstream of uptake (e.g., endo-lysosomal routing, templating efficiency, or neuron-specific toxicity).

Visualizations (from paper-reported numeric values)

A) In vivo tau spread: hTau+ / GFP− cells per mm²

Values are reported for PBS vs scramble shRNA vs LRP1 shRNA in the paper’s spread quantification.

B) RAP competition: tau uptake IC50 (nM)

Paper reports full-length soluble monomeric tau uptake IC50 and K18 uptake IC50 under RAP competition conditions.

C) Qualitative uptake pattern summary (what the paper claims)

The paper reports strong LRP1 dependency for monomeric soluble tau and for oligomers, with reduced but not full blockade for sonicated fibrils.

Tau species / fragment	Reported effect of LRP1 repression on uptake	Paper evidence type
Full-length soluble monomeric tau (2N4R)	“Almost completely” blocked	CRISPRi + flow cytometry
Tau oligomers	Significantly reduced	CRISPRi + flow cytometry
Sonicated tau fibrils	Reduced but not fully inhibited	CRISPRi + flow cytometry
Microtubule-binding repeat fragments (e.g., K18/K19)	Uptake reduced; lysine capping blocks K18 uptake	CRISPRi + lysine capping / competition

Note on uncertainty: the table is a condensation of claims from the paper text rather than re-plotted raw curves; it preserves directionality but not effect size.

Mechanistic interpretation (what is supported vs inferred)

1) Receptor identity and specificity

Supported: In a CRISPRi repression screen across LDLR-family members, LRP1 repression shows a dominant effect on tau uptake while transferrin uptake is unchanged, arguing against a generic endocytosis inhibition.
Inferred: The paper uses RAP as an LRP1-binding competitor and lysine-capping/mini-LRP domain rescues to argue that tau interacts with LRP1 through lysine-dependent salt bridge-like contacts. These are mechanistic inferences that depend on model assumptions about RAP binding and about how lysine capping preserves other tau properties besides receptor-binding.

2) From uptake to “spread”: what the paper demonstrates

Supported operationally: Reducing neuronal LRP1 expression reduces the experimental readout of tau propagation (hTau+ / GFP− cells).
Mechanistic gap: The study largely connects LRP1 to uptake and then associates uptake dependence with reduced spread. But the paper does not, within the provided text, show step-by-step in vivo trafficking/endo-lysosomal kinetics or quantitate how templating efficiency changes per transferred seed.

3) Alternative explanations to consider (within the paper’s scope)

LRP1 affects more than tau uptake: LRP1 has roles in endocytosis/trafficking and in broader extracellular ligand handling. Thus, reduced spread could reflect effects on post-uptake handling, not only initial entry. The paper’s evidence supports uptake dependence strongly, but the causality of endocytosis vs downstream propagation steps remains a testable separation.
Cell-type differences and tau species heterogeneity: The paper uses specific tau species/preparations (monomeric, oligomeric, sonicated fibrils; plus phosphorylation/mutant forms). Differences in preparation state could modulate how much is LRP1-dependent vs HSPG/proteoglycan-dependent. The paper does note distinct uptake mechanisms among tau species, and the fibril uptake is only partially inhibited, consistent with pathway partitioning.

What would most strongly disprove/limit the paper’s headline claim?

If complete genetic removal of LRP1 (not just CRISPRi repression) fails to reduce tau uptake substantially, or if other LDLR-family members compensate to restore uptake, the “LRP1 master regulator” framing would be weakened.
If tau spread reduction in vivo persists despite normalizing receptor-mediated uptake (e.g., by alternative delivery or by direct manipulation of intracellular templating), then the uptake-to-spread causal chain would be incomplete.

Author reviews (bespoke BGPT links)

Feedback:

Updated: March 25, 2026